Impact of Neuropsychological Disorders in Multiple Sclerosis
Impact of Neuropsychological Disorders on Visual Exploration, Walking Initiation and Walking in Multiple Sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Three dimensional gait analysis with eyetracking
What it measured
Main measures
Cadence of walking (in cycles.min-1)
60 days
Walking and mobilityStep length (in m)
60 days
Walking and mobilityWalking speed (in m.s-1)
60 days
Walking and mobilityRange of motion in the lower limbs in degrees
60 days
Walking and mobility
Other measures (5)
Ocular fixation time (measured in ms)
60 days
Thinking and memoryWalking and mobilityMuscle contractions determined by the electromyogram (EMG) (mV)
60 days
Walking and mobilityDisplacements (in mm) during walking
60 days
Walking and mobilityAcceleration (in mm.s-2) during walking
60 days
Walking and mobilityJoint angles
60 days
Walking and mobility
Who could take part
Relapsing MS · 18 to 55
Show the full criteria
Inclusion criteria
* Understanding and able to speak French * Carriers of MS with relapsing remitting form (RRMS-RR) with an EDSS \<4 * No significant motor, cerebellar or somesthesia disorders of the upper limbs or visual disturbances (side to a visual EDSS \<2) * Absence of corticosteroid intake in the last four weeks * Benefiting from health insurance coverage * Not showing any flare-ups or worsening of the disease in the last 6 weeks * No botulinum toxin injection for more than 4 months
Exclusion criteria
* People with previous neurological pathologies, head trauma with loss of consciousness, psychiatric pathologies, serious general ailments, perceptual or dysarthric disorders preventing verbal communication or reading, * Treatment with psychotropic drugs (except benzodiazepines and hypnotics). * Refusal to participate after clear and fair information about the study. * Adults under tutorship, curatorship or safeguard of justice * With orthopedic treatment influencing walking * Pregnant woman
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The study involves MS patients with and without neuropsychological disorders. The patient will benefit from: * A routine neuropsychological assessment, including a cognitive and emotional assessment * A clinical examination * A three-dimensional analysis of movement
Loading reviews and guidelines…
History
Started
May 2021
Main results due
Nov 2025
Finished
Dec 2025